{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '2. Dementia, altered mental status, or any psychiatric condition, or stay in an institution', 'further to an official or court order that would prohibit the understanding or rendering of', 'informed consent or participation in the study.', '3. Anticipated use of short-term prophylaxis of angioedema attacks for a pre-planned', 'procedure during the screening or study periods (Parts 1 and 2 only).', '4. Concurrent diagnosis of any other type of recurrent angioedema.', '5. Clinically significant abnormal electrocardiogram (ECG) at the screening visit. This', \"includes, but is not limited to, a QT interval corrected by Fridericia's formula (QTcF)\", '> 470 msec for women, a QTcF > 450 msec for men, PR interval > 220 msec (both', 'sexes), or ventricular and/or atrial premature contractions that are more frequent than', 'occasional, and/or as couplets or higher in grouping.', '6. Any clinically significant history of angina, myocardial infarction, syncope, clinically', 'significant cardiac arrhythmias, left ventricular hypertrophy, cardiomyopathy, or any', 'other clinically significant cardiovascular abnormality such as poorly controlled', 'hypertension.', '7. Known family history of sudden cardiac death. Family history of sudden death from HAE', 'is not exclusionary.', '8. History of or current implanted defibrillator or pacemaker.', '9. Any abnormal laboratory or urinalysis parameter at screening that, in the opinion of the', 'Investigator, is clinically significant and relevant for this study. A calculated creatinine', 'clearance (CLCR) of VI 30 mL/min or AST or ALT value > 3 X the upper limit of the', 'normal (ULN) reference range value obtained during screening is exclusionary.', '10. Prior enrollment in a BCX7353 study.', '11. Suspected C1-INH resistance in the opinion of the Investigator or Sponsor.', '12. History of alcohol or drug abuse within the previous year prior to the screening visit, or', 'current evidence of substance dependence or abuse (self-reported alcoholic intake', '> 3 drinks/day).', '13. Positive serology for human immunodeficiency virus (HIV) or current infection with', 'hepatitis B virus (HBV) or hepatitis C virus (HCV).', '14. Pregnant, planning to become pregnant during the study, or nursing.', '15. Positive drugs of abuse screen (unless drug is used as medical treatment with a', 'prescription).', '16. History of severe hypersensitivity to multiple medicinal products, or severe', 'hypersensitivity/anaphylaxis with unclear etiology.', '17. Use of androgens or tranexamic acid for prophylaxis of HAE attacks within the 28 days', 'prior to the screening visit or initiation during the study.', 'Prophylaxis is defined as administration of a medication in the absence of symptoms of', 'an HAE attack.', '43']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '18. Use of C1-INH for prophylaxis of HAE attacks within the 14 days prior to the screening', 'visit or initiation during the study. Use of a C1-INH therapy for treatment of attacks is', 'not excluded at any time, nor is C1-INH for preprocedure prophylaxis for an', 'unplanned/unforeseen procedure.', 'Prophylaxis is defined as administration of a medication in the absence of symptoms of', 'an HAE attack.', '19. Use of concomitant medications that are metabolized by cytochrome P450 (CYP) 2D6,', 'CYP2C9, CYP2C19, and CYP3A4 and have a narrow therapeutic range, within 7 days of', 'the baseline visit or planned initiation during the study (see Section 9.7.1).', '20. Use of a medication that is clinically known to prolong the QT interval and is', 'metabolized by CYP2D6, CYP2C9, CYP2C19, and/or CYP3A4 7 days prior to the', 'baseline visit or planned initiation during the study (see Section 9.7.1).', '21. Use of a medication that is transported by p-glycoprotein efflux pump (P-gp) and has a', 'narrow therapeutic range, within 7 days of the baseline visit or planned initiation during', 'the study (see Section 9.7.1).', '22. Use of an angiotensin-converting enzyme inhibitor within 7 days of the baseline visit or', 'planned initiation during the study.', '23. Initiation of an estrogen-containing hormonal contraceptive within 56 days of the', 'screening visit or planned initiation during the study (Parts 1 and 2 only). Established use', '(initiation > 56 days prior to screening) during the study is permitted.', '24. Current participation in any other investigational drug study or received another', 'investigational drug within 30 days of the Screening visit.', '25. An immediate family relationship to either Sponsor employees, the Investigator or', 'employees of the study site named on the delegation log.', '26. Held in an institution by a government or judicial order.', '8.3.', 'Subject Withdrawal from the Study and from Study Drug', '8.3.1.', 'Subject Withdrawal from the Study', 'Participation in the study is strictly voluntary; a subject may withdraw consent to contribute', 'additional study information at any point. A subject who withdraws consent will be requested to', 'attend an early termination visit to complete all end-of-study evaluations. Although a subject', 'may withdraw from the study at any time without specifying a reason for withdrawal, if known,', \"the reason for withdrawal will be recorded in the subject's medical records (source documents)\", 'and also in the CRF. If the reason for subject withdrawal is not known, the subject must be', 'contacted to establish whether the reason was an AE, and if so, this must be reported in', 'accordance with the procedures outlined in Section 12. If at any point in the study the clinic is', 'unable to contact the subject after appropriate attempts have been made, the subject will be', 'considered lost to follow-up.', 'Once subjects have withdrawn from the study, the Sponsor will no longer provide treatment', 'through the study. Following withdrawal from the study, a subject will be able to receive further', '44']\n\n###\n\n", "completion": "END"}